44
Participants
Start Date
March 31, 2005
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
SU011248; Gemcitabine
Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
Pfizer Investigational Site, Boston
Pfizer Investigational Site, Boston
Pfizer Investigational Site, Boston
Lead Sponsor
Pfizer
INDUSTRY